Physician profile
Christopher R Porter
NPI 1174616437
$3,437.09
in general payments reported to CMS, 2019-2025
14 companies · $194 in 2025
The $194 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $823 · 2020: $108 · 2021: $753 · 2022: $327 · 2023: $534 · 2024: $699 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,256 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,256.25 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,429.58 | 2021-2025 | Interstim |
| Medtronic USA, INC. | $580.61 | 2019 | |
| Astellas Pharma US INC | $398.89 | 2021-2024 | Xtandi |
| Cook Medical LLC | $211.38 | 2019-2024 | Hemospray |
| Boston Scientific Corporation | $155.99 | 2024 | Advance Xp |
| Coloplast Corp | $137.38 | 2019 | |
| Fennec Pharmaceuticals, INC. | $136.66 | 2023 | Pedmark |
| Ethicon US, LLC | $131.00 | 2022 | |
| Convatec INC. | $103.81 | 2020 | |
| Janssen Biotech, INC. | $71.71 | 2023 | Erleada |
| Viiv Healthcare Company | $33.57 | 2025 | |
| Pfizer INC. | $27.09 | 2023 | |
| Urogen Pharma, INC. | $15.60 | 2025 | |
| Travere Therapeutics, INC. | $3.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.